viewGenprex, Inc.

Genprex Inc retains pharmaceutical branding company to commercialize its lung cancer drug

the firm Addison Whitney will oversee the drug's naming process, which requires regulatory approval

Oncoprex name tag
The clinical-stage gene therapy company has developed a non-small cell lung cancer treatment, currently called Oncoprex

Genprex Inc (NASDAQ:GNPX) has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

The clinical-stage gene therapy company has developed the drug to treat non-small cell lung cancer treatment.

Addison Whitney will oversee the official naming process, which requires regulatory approval.

READ: Genprex reports positive preclinical data on its drug to treat lung cancer

"Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Chairman and CEO Rodney Varner said. "Obtaining regulatory approval of proprietary and non-proprietary drug names is a necessary step in securing marketing approval, and Addison Whitney has an impressive track record in obtaining such name approvals.”

The Austin-based company’s drug fights non-small cell lung cancer by transporting cancer-fighting genes to cancerous cells.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Genprex, Inc.

Price: 3.37 USD

Market: NASDAQ
Market Cap: $130.99 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...


Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read